OMER — Omeros Corporation
NASDAQ · Healthcare · Biotechnology
$19.41
+$0.66 (+3.49%)
Omeros Corporation (OMER) is a biotechnology company listed on NASDAQ. It is led by Gregory A. Demopulos M.D., based in The Omeros Building, Seattle, WA, United States, 98119, with about 202 employees. Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Net income was -$30.9M. OMER currently screens at market cap $174.0M.
Use this OMER page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OMER quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OMER SEC filings page. Lician reads the product cache first so this HTML stays unique to Omeros Corporation even when a live quote feed is slow.
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
OMER Key Statistics
Market Cap
$174.02M
Volume
87,964
Previous Close
$19.28
Day Range
$18.85 – $19.08
EPS
$0.00
Revenue
$0.00
Net Income
-$156.81M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
202
OMER Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$156.81M | -$117.81M | $47.42M | $194.24M |
| EPS (Diluted) | $0.00 | $0.00 | $0.76 | $3.12 |
Total Assets
$277.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.40M
Operating Cash Flow
-$148.80M
Free Cash Flow
$0.00
Omeros Corporation Company Information
- Co-Founder, Chairman, CEO & President
- Gregory A. Demopulos M.D.
- Headquarters
- The Omeros Building, Seattle, WA, United States, 98119
- Website
- www.omeros.com
- Phone
- 206 676 5000
- IPO / Founded
- 2009-10-08
- Sector
- Healthcare
- Industry
- Biotechnology